The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVela Technologies Regulatory News (VELA)

Share Price Information for Vela Technologies (VELA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0115
Bid: 0.011
Ask: 0.012
Change: 0.00 (0.00%)
Spread: 0.001 (9.091%)
Open: 0.0115
High: 0.0115
Low: 0.0115
Prev. Close: 0.0115
VELA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on investment in 3Legs Resources plc

4 Nov 2015 12:18

RNS Number : 5452E
Vela Technologies PLC
04 November 2015
 



Vela Technologies plc

("Vela" or the "Company")

Update on investment in 3Legs Resources plc

Vela Technologies plc (AIM: VELA), the investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released earlier today by 3Legs Resources plc ("3Legs").

As at the date of this announcement Vela holds 23,500,000 shares in 3Legs which represents 3.80 per cent. of the existing voting rights of 3Legs.

Vela's shareholding in 3Legs has been acquired at an average price of 0.213 pence per share for a total consideration of approximately £50,090.

3Legs is an Isle of Man incorporated investing company whose shares are traded on AIM. The investing policy of 3Legs is to seek to invest in and/or acquire companies within the life sciences and related technologies sector. As announced today 3Legs has recently signed non-binding heads of terms in connection with the proposed acquisition by 3Legs of SalvaRx Limited ("SalvaRx"), a company in which 3Legs owns an 11.1 per cent. shareholding. On 30 September, 3Legs reported that it had subscribed £215,000 for new shares in SalvaRx in conjunction with a subscription for the same amount by Jim Mellon and Greg Bailey, both directors and substantial shareholders of 3Legs.

A copy of 3Legs's announcement is below and a link to the 3Legs announcement can be found at: http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12567318.html 

For further information please contact:

Vela Technologies plc

Brent Fitzpatrick, Non-Executive Chairman

Antony Laiker, Director

 

 

Tel: +44 (0) 7802 262 443

 

Allenby Capital Limited

(Nominated Adviser)

Nick Athanas/Katrina Perez/James Reeve

 

Vicarage Capital Limited

(Broker)

Rupert Williams/Jeremy Woodgate

 

 

Tel: +44 (0) 20 3328 5656

 

 

 

Tel: +44 (0) 20 3651 2910

 

3Legs Resources plc

("3Legs" or the "Company")

Proposed Acquisition and Suspension of Trading

3Legs announces that, in accordance with Rule 15 of the AIM Rules for Companies ("AIM Rules"), the Company's shares have been suspended from trading on AIM from 7.30 a.m. today as a result of the Company not having completed an acquisition which constitutes a reverse takeover under the AIM Rules, or otherwise implemented its investing policy within 12 months of becoming an investing company. The Company is actively working to implement its investing policy and the Board is pleased to provide the following update.

The Company has recently signed non-binding heads of terms in connection with the proposed acquisition of SalvaRx Limited ("SalvaRx"), a company in which 3Legs owns an 11.1 per cent. shareholding. On 30 September, the Company reported that it had subscribed £215,000 for new shares in SalvaRx in conjunction with a subscription for the same amount by Jim Mellon and Greg Bailey, both directors and substantial shareholders of 3Legs.

SalvaRx owns 60.5% of iOx Therapeutics Limited ("iOx"), a new company which is developing a series of compounds for cancer immunotherapy. As previously announced, iOx's technology is based on a discovery by Professor Vincenzo Cerundolo MD, PhD, the Director of the Human Immunology Unit at the Weatherall Institute of Molecular Medicine at Oxford University and supported by the Ludwig Institute for Cancer Research. Its compounds stimulate invariant natural killer T cells, and preclinical testing in several cancer models suggest the compounds can inhibit the growth of tumours.

The transaction, should it proceed, will be structured by way of an acquisition of all the shares in SalvaRx not already owned by Company with the consideration being satisfied by the issue of new shares in the Company. Due to its size in relation to the Company, the proposed acquisition of SalvaRx would constitute a "reverse takeover" under the AIM Rules. Therefore the Company's shares will remain suspended until such time as either an admission document setting out details of the proposed acquisition is published or, in the event that the transaction does not proceed, the Company has taken other steps to implement its Investing Policy.

In the event that the Company is unable to implement its investing policy within the next six months (i.e. by 4 May 2016), admission of the Company's shares will be cancelled in accordance with Rule 41 of the AIM Rules.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBIBTTMBBMBJA
Date   Source Headline
2nd Jun 201610:06 amRNSHolding(s) in Company
6th May 20161:50 pmRNSFurther investment in BTL Group Ltd.
15th Apr 20167:00 amRNSCompletion of investment in Portr Limited
5th Apr 20163:10 pmRNSChange of Registered Office
31st Mar 20165:30 pmRNSTotal Voting Rights
30th Mar 20161:32 pmRNSUpdate on investment in BTL Group Ltd
29th Mar 20162:15 pmRNSHolding(s) in Company
22nd Mar 20169:05 amRNSHolding(s) in Company
8th Mar 201612:11 pmRNSPlacing and proposed investment in Portr Limited
3rd Mar 201612:42 pmRNSUpdate on investment in 3Legs Resources plc
19th Feb 20169:50 amRNSUpdate on investment in BTL Group Ltd
19th Jan 20169:33 amRNSUpdate on investment in BTL Group Ltd.
13th Jan 20167:00 amRNSUpdate on investment in StreamTV Networks
23rd Dec 201512:05 pmRNSHalf Yearly Report
9th Dec 201510:45 amRNSUpdate on investment in Portr - launch at Heathrow
4th Dec 20159:52 amRNSUpdate on investment in StreamTV Networks Inc.
6th Nov 20158:52 amRNSInvestment in BTL Group Ltd
4th Nov 201512:18 pmRNSUpdate on investment in 3Legs Resources plc
23rd Oct 20157:00 amRNSGrant of share options
19th Oct 201512:15 pmRNSDirectors' Dealings
16th Oct 20151:55 pmRNSUpdate on investment in Revolve Performance Ltd
14th Oct 20159:54 amRNSUpdate on proposed Blockchain investment
7th Oct 201511:25 amRNSDTL Investment Update - Nektan plc Financing
1st Oct 201512:40 pmRNSTotal Voting Rights
28th Sep 20157:00 amRNSUpdate on DTL Investment - Nektan plc
25th Sep 201510:55 amRNSResult of AGM
18th Sep 201511:50 amRNSResult of General Meeting
2nd Sep 20152:28 pmRNSFinal Results
26th Aug 20157:00 amRNSProposed Investment and Placing to raise £250,000
10th Aug 20157:00 amRNSUpdate on investment in The Social Superstore
31st Jul 201510:03 amRNSUpdate - Portr £3.3 million Series A funding round
27th Jul 20151:30 pmRNSUpdate on Portr - launch at Gatwick Airport
19th Jun 20157:00 amRNSInvestment in Revolve Performance Limited
16th Jun 20154:14 pmRNSHolding(s) in Company
9th Jun 20153:30 pmRNSUpdate on investment in 3Legs Resources plc
29th May 201512:48 pmRNSUpdate on investment in DTL
14th May 201510:35 amRNSHolding(s) in Company
14th May 20159:50 amRNSUpdate on investment in 3Legs Resources plc
5th May 20157:01 amRNSUpdate on investment in Disruptive Tech Limited
16th Apr 20157:00 amRNSCorporate update
9th Apr 201510:47 amRNSUK Investor Show 2015
31st Mar 20155:30 pmRNSTotal Voting Rights
30th Mar 20157:00 amRNSUpdate on investment in 3Legs Resources plc
19th Mar 20157:00 amRNSChange of Broker
10th Mar 20157:02 amRNSInvestment in 3Legs Resources plc
5th Mar 20155:52 pmRNSHolding(s) in Company
17th Feb 20155:10 pmRNSProposed grant of options
16th Feb 20157:00 amRNSPlacing to Raise £300,000
19th Dec 20144:00 pmRNSHalf Yearly Report
11th Nov 201411:12 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.